Furthermore, clinical-grade fully human anti-CXCL10 monoclonal antibodies, such as MDX-1100 (eldelumab), have already been developed and tested in Phase II clinical trials for rheumatoid arthritis and ulcerative colitis [193]. Here, CXCL10 is linked to rheumatoid arthritis.